Bedaquiline
Johnson & Johnson’s TB drug deal will fail to reach all those in need
A recent deal struck between Johnson & Johnson and the Global Drug Facility promises improved access to bedaquiline in a number of low income countries, but fails to address structural problems
Sí, podemos impedir que las patentes obstaculicen el tratamiento de la tuberculosis
Un día antes del Día Mundial de la Tuberculosis, la Oficina de Patentes de la India rechazó la solicitud del gigante farmacéutico Jannsen de prorrogar la patente del medicamento bedaquilina.
Yes, we can stop patents getting in the way of TB treatment
A day ahead of World TB Day, the Indian Patent Office rejected pharma giant Jannsen’s application for a patent extension on drug bedaquiline. If the patent had been extended, public and family budgets would have remained burdened by unjustifiably high costs of the drug
- Dr. Oz’s nomination fuels fears for crucial health programs
- Columbia expels and sanctions pro-Palestine students amid increased pressure from Trump administration
- Moncada, Nasralla, and Asfura emerge as frontrunner candidates for Honduran presidential elections in November
- Brazil-China relations strengthen as economic and diplomatic ties deepen
- Greenland’s election brings unexpected shifts
